FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4221036746> ?p ?o ?g. }

• W4221036746 endingPage "84" @default.
• W4221036746 startingPage "80" @default.
• W4221036746 abstract "To investigate the efficacy and safety of nasal continuous positive airway pressure (NCPAP) combined with inhalation of pulmonary surfactant (PS) using vibrating mesh nebulizers in the treatment of neonatal respiratory distress syndrome (RDS).A prospective study was performed on premature infants with RDS admitted to the First Affiliated Hospital of Bengbu Medical College between December 2020 and June 2021. They were randomly assigned into vibrating mesh atomization technology group and intubation-surfactant-extubation (INSURE) technology group. The two groups were treated with NCPAP combined with PS. PS in the vibrating mesh atomization technology group was inhaled into the lungs by the new vibrating mesh atomization technology, while PS in the INSURE group was injected into the lungs by endotracheal tube. The pH value, arterial partial pressure of carbon dioxide (PaCO2), oxygenation index (PaO2/FiO2), mechanical ventilation via endotracheal tube (MVET) demand rate, duration of respiratory support, secondary use of PS, complications, and hospital mortality were compared between the two groups. The occurrences of adverse events in the two groups were recorded.A total of 42 preterm infants were finally enrolled, including 20 cases in the vibrating mesh atomization technology group and 22 cases in the INSURE technology group. There were no significant differences in blood gas analysis and PaO2/FiO2 before PS administration between the two groups. One hour after PS administration, blood gas analysis and PaO2/FiO2 were significantly improved in both groups. Compared with the INSURE technology group, the improvement of PaO2/FiO2 was more obvious in the vibrating mesh atomization technology group [mmHg (1 mmHg≈0.133 kPa): 198±34 vs. 173±39, P < 0.05], but no significant difference in pH value or PaCO2 was found between the two groups. The duration of respiratory support in the vibrating mesh atomization technology group was significantly shorter than that in the INSURE technology group (hours: 96±13 vs. 120±18, P < 0.01), but there was no statistical difference in MVET demand rate [5.0% (1/20) vs. 13.6% (3/22), P > 0.05]. The incidence of periventricular-intraventricular hemorrhage (PVH-IVH) in the vibrating mesh atomization technology group was less than that in the INSURE technology group [0% (0/20) vs. 18.2% (4/22)], but no statistical difference was found (P > 0.05). No significant differences in the secondary use rate of PS and incidence of bronchopulmonary dysplasia (BPD) or other complications were found between the vibrating mesh atomization technology group and the INSURE technology group [5.0% (1/20) vs. 9.1% (2/22), 5.0% (1/20) vs. 4.5% (1/22), both P > 0.05]. There were no deaths or serious adverse events such as pneumothorax, pulmonary hemorrhage, periventricular leukomalacia (PVL), retinopathy of prematurity (ROP), and necrotizing enterocolitis (NEC) in both groups.Compared with the INSURE technique, NCPAP combined with vibrating mesh atomization technology was also effective and safe in the treatment of RDS, which could significantly improve PaO2/FiO2 and shorten the duration of respiratory support. Thus, it was worthy of clinical popularization and application." @default.
• W4221036746 created "2022-04-03" @default.
• W4221036746 creator A5028462736 @default.
• W4221036746 creator A5029529442 @default.
• W4221036746 creator A5029685658 @default.
• W4221036746 creator A5033632697 @default.
• W4221036746 creator A5037989560 @default.
• W4221036746 creator A5045839676 @default.
• W4221036746 creator A5047739496 @default.
• W4221036746 creator A5061402622 @default.
• W4221036746 creator A5066349538 @default.
• W4221036746 creator A5069360186 @default.
• W4221036746 creator A5089834503 @default.
• W4221036746 creator A5090096320 @default.
• W4221036746 date "2022-01-01" @default.
• W4221036746 modified "2023-09-28" @default.
• W4221036746 title "[Efficacy and safety of inhalation of pulmonary surfactant using vibrating mesh nebulizers combined with nasal continuous positive airway pressure in the treatment of neonatal respiratory distress syndrome]." @default.
• W4221036746 doi "https://doi.org/10.3760/cma.j.cn121430-20210602-00815" @default.
• W4221036746 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35307066" @default.
• W4221036746 hasPublicationYear "2022" @default.
• W4221036746 type Work @default.
• W4221036746 citedByCount "1" @default.
• W4221036746 countsByYear W42210367462022 @default.
• W4221036746 crossrefType "journal-article" @default.
• W4221036746 hasAuthorship W4221036746A5028462736 @default.
• W4221036746 hasAuthorship W4221036746A5029529442 @default.
• W4221036746 hasAuthorship W4221036746A5029685658 @default.
• W4221036746 hasAuthorship W4221036746A5033632697 @default.
• W4221036746 hasAuthorship W4221036746A5037989560 @default.
• W4221036746 hasAuthorship W4221036746A5045839676 @default.
• W4221036746 hasAuthorship W4221036746A5047739496 @default.
• W4221036746 hasAuthorship W4221036746A5061402622 @default.
• W4221036746 hasAuthorship W4221036746A5066349538 @default.
• W4221036746 hasAuthorship W4221036746A5069360186 @default.
• W4221036746 hasAuthorship W4221036746A5089834503 @default.
• W4221036746 hasAuthorship W4221036746A5090096320 @default.
• W4221036746 hasConcept C105922876 @default.
• W4221036746 hasConcept C126322002 @default.
• W4221036746 hasConcept C127413603 @default.
• W4221036746 hasConcept C141983124 @default.
• W4221036746 hasConcept C200457457 @default.
• W4221036746 hasConcept C2776006263 @default.
• W4221036746 hasConcept C2777257755 @default.
• W4221036746 hasConcept C2777785262 @default.
• W4221036746 hasConcept C2778716859 @default.
• W4221036746 hasConcept C2779547634 @default.
• W4221036746 hasConcept C42219234 @default.
• W4221036746 hasConcept C534529494 @default.
• W4221036746 hasConcept C71924100 @default.
• W4221036746 hasConcept C78519656 @default.
• W4221036746 hasConceptScore W4221036746C105922876 @default.
• W4221036746 hasConceptScore W4221036746C126322002 @default.
• W4221036746 hasConceptScore W4221036746C127413603 @default.
• W4221036746 hasConceptScore W4221036746C141983124 @default.
• W4221036746 hasConceptScore W4221036746C200457457 @default.
• W4221036746 hasConceptScore W4221036746C2776006263 @default.
• W4221036746 hasConceptScore W4221036746C2777257755 @default.
• W4221036746 hasConceptScore W4221036746C2777785262 @default.
• W4221036746 hasConceptScore W4221036746C2778716859 @default.
• W4221036746 hasConceptScore W4221036746C2779547634 @default.
• W4221036746 hasConceptScore W4221036746C42219234 @default.
• W4221036746 hasConceptScore W4221036746C534529494 @default.
• W4221036746 hasConceptScore W4221036746C71924100 @default.
• W4221036746 hasConceptScore W4221036746C78519656 @default.
• W4221036746 hasIssue "1" @default.
• W4221036746 hasLocation W42210367461 @default.
• W4221036746 hasOpenAccess W4221036746 @default.
• W4221036746 hasPrimaryLocation W42210367461 @default.
• W4221036746 hasRelatedWork W13098972 @default.
• W4221036746 hasRelatedWork W13636133 @default.
• W4221036746 hasRelatedWork W13972674 @default.
• W4221036746 hasRelatedWork W16813369 @default.
• W4221036746 hasRelatedWork W2828659 @default.
• W4221036746 hasRelatedWork W4701558 @default.
• W4221036746 hasRelatedWork W6204446 @default.
• W4221036746 hasRelatedWork W6791187 @default.
• W4221036746 hasRelatedWork W7135341 @default.
• W4221036746 hasRelatedWork W99728 @default.
• W4221036746 hasVolume "34" @default.
• W4221036746 isParatext "false" @default.
• W4221036746 isRetracted "false" @default.
• W4221036746 workType "article" @default.